Sustained Release Ocular Bevacizumab for the treatment of wet acute macular dege...
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration
This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to impr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
BlueDot
A long acting constant release ocular implant for the susta...
71K€
Cerrado
PTQ-09-02-01226
Formulación en microesferas para transporte intravítreo de f...
55K€
Cerrado
PID2020-114894RB-I00
INSERTO OCULAR FABRICADO MEDIANTE ELECTROHILADO COAXIAL DE C...
105K€
Cerrado
Light4Sight
Light activated carriers for the controlled delivery of ther...
225K€
Cerrado
MAT2009-14609-C02-01
MATERIALES DE LAS LENTES DE CONTACTO: INTERACCIONES ENTRE EL...
7K€
Cerrado
NeoVasculoStop
NATURAL INTRAOCULAR PHOTOACTIVATION OF COMPOUNDS TO FIGHT RE...
3M€
Cerrado
Información proyecto STROBE
Duración del proyecto: 6 meses
Fecha Inicio: 2015-04-10
Fecha Fin: 2015-10-31
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Sustained Release Ocular Bevacizumab for the treatment of wet acute macular degeneration
This feasibility study is to verify the technical and economic viability of a sustained release bevacizumab product (SR Bevacizumab) to improve the safety, cost-effectiveness and patient acceptability for the treatment of wet age-related macular degeneration (AMD). AMD is the leading cause of blindness in those aged over 50 and causes blurring, distortion and loss of central vision and almost always affects quality of life. Prototype SR Bevacizumab products will be manufactured using CriticalMix, an advanced manufacturing and processing technology developed by Critical Pharmaceuticals, which will encapsulate bevacizumab in biodegradable polymers suitable for sustained release of the drug in the eye.